Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.27 USD | -5.22% |
|
-3.79% | -9.93% |
06-11 | IntelGenx Reports Launch of Sale and Investment Solicitation Process | MT |
05-23 | Atai Life Sciences N.V. Announces Board and Supervisory Board Changes | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.93% | 213M | - | ||
+34.01% | 51.07B | B- | ||
+34.78% | 38.61B | A | ||
-8.02% | 38.78B | B | ||
-8.98% | 27.32B | C | ||
+12.56% | 26.35B | B- | ||
-19.62% | 19.46B | B | ||
+39.18% | 13.58B | B+ | ||
+31.47% | 12.46B | C+ | ||
-3.40% | 11.75B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ATAI Stock
- Ratings Atai Life Sciences N.V.